Michael A. Carducci

Phase I studies

G. Shapiro, H. Hurwitz, M. Carducci, 2010 .

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

A. Muehler, K. Venkatakrishnan, J. Nemunaitis, 2014, Investigational New Drugs.

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

G. Wilding, M. Carducci, D. Mahalingam, 2016, British Journal of Cancer.

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.

M. Carducci, R. Pili, Brant W. Hager, 2001, Cancer research.

Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer.

D. Yaden, A. Garcia-Romeu, Michael A. Carducci, 2023, Cancer.

Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements

J. Verweij, H. Gelderblom, E. Garrett-Mayer, 2008, Clinical pharmacology and therapeutics.

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

J. Baselga, J. Seoane, L. Paz-Ares, 2014, Clinical Cancer Research.

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

M. Carducci, M. Eisenberger, C. Sweeney, 2010, Cancer Chemotherapy and Pharmacology.